This bill, titled the "Innovative Therapies Centers of Excellence Act of 2025," amends title 38, United States Code, to require the Secretary of Veterans Affairs to designate and establish not less than five innovative therapies centers of excellence within Department medical facilities. These centers will be geographically distributed and established based on recommendations from the Under Secretary for Health and a peer review panel's assessment of scientific and clinical merit. The bill authorizes an appropriation of $30,000,000 annually for the research and education activities of these centers, subject to the availability of appropriations. To be designated, facilities must demonstrate affiliations with accredited medical schools (including those for innovative therapies, psychiatry, and social work), the ability to attract skilled scientists, and an advisory committee involving veterans. They must also have the capability to conduct evaluations, coordinate activities nationally, and develop a consortium of providers to expand access to care. A key provision includes the development of a national repository for collecting data on health services delivered to veterans seeking innovative therapies. The centers will focus on treating "covered conditions" such as Anxiety Bipolar disorder Chronic pain Depression Parkinson's disease Post-traumatic stress disorder (PTSD) Substance use disorder using "innovative therapies" including 3,4-Methylenedioxy-methamphetamine (MDMA) 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) Ibogaine Ketamine Psilocybin , with the Under Secretary having the authority to designate additional conditions and therapies. The Under Secretary for Health is also required to submit annual reports to Congress detailing the centers' activities, key findings, and recommendations for improving therapy delivery to veterans.